Joshua Reed
2019 - Aldeyra Therapeutics
In 2019, Joshua Reed earned a total compensation of $2.2M as Chief Financial Officer at Aldeyra Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $140,244 |
|---|---|
| Option Awards | $1,359,210 |
| Salary | $377,000 |
| Stock Awards | $238,578 |
| Other | $66,243 |
| Total | $2,181,275 |
Reed received $1.4M in option awards, accounting for 62% of the total pay in 2019.
Reed also received $140.2K in non-equity incentive plan, $377K in salary, $238.6K in stock awards and $66.2K in other compensation.
Rankings
In 2019, Joshua Reed's compensation ranked 5,479th out of 13,971 executives tracked by ExecPay. In other words, Reed earned more than 60.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,479 out of 13,971 | 61st |
Division Manufacturing | 2,045 out of 5,701 | 64th |
Major group Chemicals And Allied Products | 727 out of 2,200 | 67th |
Industry group Drugs | 611 out of 1,886 | 68th |
Industry Pharmaceutical Preparations | 450 out of 1,398 | 68th |
Source: SEC filing on April 27, 2020.
Reed's colleagues
We found two more compensation records of executives who worked with Joshua Reed at Aldeyra Therapeutics in 2019.